Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Adagrasib oral dose of 400 mg twice daily tablets Phase 2 Results Expected
Adagrasib oral dose of 400 mg twice daily tablets • Advanced NSCLC
Krazati
Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.
